Close
Achema middle east
swop processing & packaging

Smart-Pill Technology

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Artificial Intelligence in Pharmaceutical Process Control Trends

Artificial Intelligence in Pharmaceutical Process Control: What's Now and...

Using Digital Twins to Optimize Pharmaceutical Plant Performance

The pharmaceutical manufacturing sector stands at the forefront of...

Integration of Digital Biology with Pharmaceutical Manufacturing

Integration of Digital Biology with Pharmaceutical Manufacturing Workflows The pharmaceutical...

Novartis says it plans to submit its microchip containing ‘smart-pill’ technology to European regulators within 18 months. Novartis is currently using the technology on an already-approved drug used to prevent organ rejection in transplant patients , but is looking at incorporating the sensor-based technology into other medications for which compliance is critical, such as cardiovascular and oncology drugs.

The silicon and metal digestible sensor within the tablet, which is activated by stomach acid upon ingestion, is able to transmit data via wireless and Bluetooth connections to a patch worn by the patient, and from there, to a smartphone or a doctor’s computer.

Anticipating that once the sensor-based technology is regulatory approved, the ‘smart-pill’ platform will be transferrable to different drugs, Mundel said future ‘smart-pill’ variants will be able to collect more advanced data, such as a patient’s heart rate, temperature and body movement, to ensure a drug is working effectively.

Because the tiny chips are added to existing drugs, Novartis does not expect to have to conduct full-scale clinical trials to prove the new products work. Instead, it aims to do “bioequivalence tests” to show they are the same as the original. A bigger issue may be what checks should be put in place to protect patients’ personal medical data as they are transmitted from inside their bodies by wireless and Bluetooth.

 

Latest stories

Related stories

Artificial Intelligence in Pharmaceutical Process Control Trends

Artificial Intelligence in Pharmaceutical Process Control: What's Now and...

Using Digital Twins to Optimize Pharmaceutical Plant Performance

The pharmaceutical manufacturing sector stands at the forefront of...

Integration of Digital Biology with Pharmaceutical Manufacturing

Integration of Digital Biology with Pharmaceutical Manufacturing Workflows The pharmaceutical...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »